Prediagnostic plasma adiponectin and survival among patients with colorectal cancer.

Abstract

Circulating adiponectin is inversely related to the risk of colorectal cancer (CRC). However, its influence on CRC survival is unclear. We conducted a prospective study to evaluate the association between prediagnostic plasma levels of adiponectin and mortality in patients with CRC. We identified 621 incident CRC cases who provided blood specimens prior to diagnosis within the Nurses' Health Study (NHS) and Health Professionals Follow-up Study (HPFS). Cox proportional hazards models were used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs). After a median follow-up of 9 years, there were 269 (43%) total deaths, of which 181 (67%) were due to CRC. Compared with participants in the lowest quartile of adiponectin, those in the highest quartile had multivariate HRs of 1.89 (95% CI, 1.21-2.97; P trend = 0.01) for CRC-specific mortality and 1.66 (95% CI, 1.15-2.39; P trend = 0.009) for overall mortality. The apparent increased risk in CRC-specific mortality was more pronounced in patients with metastatic disease (HR 3.02, 95% CI, 1.50-6.08). Among patients with CRC, prediagnostic HHS Public Access Author manuscriptCancer Prev Res (Phila). Author manuscript; available in PMC 2016 December 01. Published in final edited form as:Cancer Prev Res (Phila). 2015 December ; 8(12): 1138 8(12): -1145 8(12): . doi:10.1158 8(12): /1940. Author Manuscript Author ManuscriptAuthor ManuscriptAuthor Manuscript plasma adiponectin is associated with an increased risk of CRC-specific and overall mortality, and is more apparent in patients with metastatic disease. Adiponectin may be a marker for cancers which develop through specific pathways that may be associated with worsened prognosis. Further studies are needed to validate these findings.

Circulating Leptin, Adiponectin, and Tumor Necrosis Factor-Alpha in Patients Undergoing Surgery Due to Colorectal Cancer

“…Moreover, a low postoperative/preoperative ADP ratio is recognized as a risk factor for postoperative infection in patients undergoing surgery due to gastric and CRC [12], and, therefore, some functional foods (soy genistein extract, lychee-derived low-molecular-weight polyphenol, olive extract, and turmeric) have been proposed to promote ADP secretion and thus inhibit cancer occurrence and recurrence [40]. On the other hand, prediagnostic low plasma ADP concentration is associated with increased CRC-specific and overall mortality [43], although Chun et al [30] suggest that dysregulation between high LEP and low ADP secretion (i.e., a low ADP-to-LEP ratio) is more important in colorectal carcinogenesis.…”

Adiponectin and Thyroid Cancer: Insight into the Association between Adiponectin and Obesity

“…Furthermore, Housa et al [138] found that compared with organ-confined prostate cancer, levels of circulating APN are higher in locally advanced cancer. More interestingly, circulating APN has been demonstrated to be positively correlated with the all-cause mortality rate in most clinical diseases, including breast cancer and colorectal cancer [139][140][141].…”

Untitled

“…Subsequently, however, the majority of studies have shown a positive association or no association of adiponectin with all-cause mortality and cardiovascular mortality [69]. These associations were described in a wide range of clinical conditions, in different genders and diverse ethnicities, and in the general population of older individuals [20,53,[104][105][106]; older patients with weight loss, low skeletal-muscle mass, and poor physical functioning [24]; elderly people with T2DM [107]; T2DM patients with acute coronary syndrome [21]; elderly men with chronic heart failure [104]; patients with chronic heart failure and cachexia [108]; myocardial infarction patients [109]; stable ischemic heart disease [110]; individuals with diabetes and recent acute coronary syndrome [21]; acute stroke patients [111]; peripheral artery diseases [112]; Japanese hemodialysis patients [113]; end-stage renal disease in patients with T1DM and T2DM [114]; cancer [115]; women with breast cancer [116]; and patients with colorectal cancer [117].…”